[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344086-105":59,"doc-detail-344086-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","biomarkers-and-potential-therapeutic-targets-driving-progression-of-non-alcoholic-steatohepatitis-to-hepatocellular-carcinoma-predicted-through-transcriptomic-analysis","Biomarkers and potential therapeutic targets driving progression of non-alcoholic steatohepatitis to hepatocellular carcinoma predicted through transcriptomic analysis","","Non-alcoholic steatohepatitis (NASH) is a highly prevalent chronic liver condition with the ability to progress to cirrhosis and hepatocellular carcinoma (HCC). Effective therapies to prevent this transition remain limited, creating demand for reliable molecular biomarkers and therapeutic targets. Using six GEO microarray datasets, robust rank aggregation identified differentially expressed genes linked to NASH activity and disease stage. Consensus clustering defined molecular subtypes, while single-cell analysis assessed cell-type-specific gene patterns and interactions. Core genes were evaluated for prognostic value in TCGA, clinical utility, drug sensitivity in GDSC, and immunotherapy relevance in TIDE, highlighting four candidates tied to HCC progression and treatment responsiveness.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/biomarkers-and-potential-therapeutic-targets-driving-progression-of-non-alcoholic-steatohepatitis-to-hepatocellular-carcinoma-predicted-through-transcriptomic-analysis/344086/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/biomarkers-and-potential-therapeutic-targets-driving-progression-of-non-alcoholic-steatohepatitis-to-hepatocellular-carcinoma-predicted-through-transcriptomic-analysis/344086.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study on NASH and HCC?","Question",{"text":112,"@type":113},"To identify biomarkers and potential therapeutic targets that drive the progression of NASH to hepatocellular carcinoma, using transcriptomic and bioinformatic analyses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were differentially expressed genes identified in this research?",{"text":117,"@type":113},"Six GEO microarray datasets were processed using Robust Rank Aggregation (RRA) to identify robust upregulated and downregulated genes.",{"name":119,"@type":110,"acceptedAnswer":120},"Which genes were highlighted as core to HCC prognosis and therapy responsiveness?",{"text":121,"@type":113},"TREM2, GDF15, TTC39A, and ANXA2 were identified as core genes associated with HCC prognosis and treatment responsiveness, particularly for immune therapy in NASH-associated HCC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344086,1790198487,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","TYPE Original Research PUBLISHED 04 December 2024 DOI 10.3389/fimmu.2024.1502263  \nOPEN ACCESS  \nEDITED BY  \nYu-Chan Chang,  \nNational Yang Ming Chiao Tung University, Taiwan  \nREVIEWED BY  \nWei Chen,  \nCapital Medical University, China Wencheng Zhang,  \nTongji University, China  \n*CORRESPONDENCE  \nJing Xiong  \n[jxiong@cpu.edu.cn](jxiong@cpu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 27 September 2024  \nACCEPTED 11 November 2024  \nPUBLISHED 04 December 2024  \nCITATION  \nFan H, Wang R, Wen B and Xiong J (2024) Biomarkers and potential therapeutic targets driving progression of non-alcoholicsteatohepatitis to hepatocellular carcinoma predicted through transcriptomic analysis. Front. Immunol. 15:1502263 .  \ndoi: 10.3389/fimmu.2024.1502263  \nCOPYRIGHT  \n© 2024 Fan, Wang, Wen and Xiong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nBiomarkers and potential therapeutic targets driving progression of non-alcoholicsteatohepatitis to hepatocellular carcinoma predicted through transcriptomic analysis  \nHui Fan 1†, Rong Wang 2†, Bin Wen 1 and Jing Xiong 1*  \n1 Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, China, 2State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China  \nBackground: Non-alcoholic steatohepatitis (NASH) is the most prevalent chronic liver condition globally, with potential progression to cirrhosis, and even hepatocellular carcinoma (HCC) . The increasing prevalence of NASH underscores the urgent need for advanced diagnostic and therapeutic strategies. Despite its widespread impact, effective treatments to prevent the progression of NASH remain elusive, highlighting the critical importance of innovative molecular techniques in both the diagnosis and management of this disease.  \nMethods: Six microarray datasets available in GEO were used to perform Robust Rank Aggregation (RRA) to identify differentially expressed genes (DEGs).Weidentiﬁed 62 robust upregulated genes and 24 robust downregulated genes. These genes were undergone Gene Ontology enrichment analysis and further examination for expression correlation with NAS score. Molecular subtypes were generated using “ConsensusClusterPlus” on identiﬁed genes, which were further assessed for tumor stage relevance, expression differences in adjacent and tumor tissues, and impact on survival in TCGA liver cancer patients. Single-cell analysis was then used to explore the genes across different cell types and subgroups as well as cell-type interactions. The clinical utility of predicted core genes was highlighted through decision curve analysis, with emphasis on HCC prognosis. The GDSC database was used to evaluate the relationship between the predicted core genes and drug sensitivity, while the TIDE database was used to evaluate their relationship with immunotherapy.  \nResults: Four core genes, TREM2, GDF15, TTC39A, and ANXA2, were identiﬁed as key to inﬂuencing HCC prognosis and therapy responsiveness, especially immune treatment efﬁcacy in NASH-associated HCC.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nConclusion: The core genes may act as critical biomarkers driving the progression of NASH to HCC. They are potential novel targets for the diagnosis and treatment of NASH progression, offering innovative perspectives for its clinical management.  \nKEYWORDS  \nnon-alcoholic steatohepatitis, triggering receptor expressed on myeloid cells 2, Annexin A2, growth/differentiation factor-15, tetratricopeptide repeat dom","cbCaiqf1wsAsBznA","https://ap.wps.com/l/cbCaiqf1wsAsBznA","pdf",19253414,"English","# Introduction\n## Methods\n## Results\n## Conclusion","[{\"question\":\"What is the main goal of this study on NASH and HCC?\",\"answer\":\"To identify biomarkers and potential therapeutic targets that drive the progression of NASH to hepatocellular carcinoma, using transcriptomic and bioinformatic analyses.\"},{\"question\":\"How were differentially expressed genes identified in this research?\",\"answer\":\"Six GEO microarray datasets were processed using Robust Rank Aggregation (RRA) to identify robust upregulated and downregulated genes.\"},{\"question\":\"Which genes were highlighted as core to HCC prognosis and therapy responsiveness?\",\"answer\":\"TREM2, GDF15, TTC39A, and ANXA2 were identified as core genes associated with HCC prognosis and treatment responsiveness, particularly for immune therapy in NASH-associated HCC.\"}]","Biomarkers and potential therapeutic targets driving progression of non-alcoholic steatohepatitis to hepatocellular carcinoma predicted through transcriptomic analysis | PDF",1790052979,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d467f92f2eb5e3fa8a624aaacea7a63f.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01b4c4a304522fb321b5984c6b0f6a58.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cf684254e45a9866717092f5e10a21e.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03822cc7c1b7f30ea681b2c7a3df3237.webp",980,1385]